National Bank of Canada FI Has $30.19 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

National Bank of Canada FI lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 73,028 shares of the company's stock after acquiring an additional 10,592 shares during the quarter. National Bank of Canada FI owned approximately 0.09% of IDEXX Laboratories worth $30,193,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth approximately $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $38,000. Crews Bank & Trust acquired a new position in IDEXX Laboratories in the 4th quarter valued at approximately $41,000. Finally, BankPlus Trust Department acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $60,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded down $17.03 during trading hours on Friday, hitting $393.73. 1,635,645 shares of the stock were exchanged, compared to its average volume of 592,305. IDEXX Laboratories, Inc. has a one year low of $390.11 and a one year high of $548.88. The company's 50 day moving average is $435.55 and its 200 day moving average is $440.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $31.91 billion, a P/E ratio of 36.90, a P/E/G ratio of 3.41 and a beta of 1.39.

Remove Ads

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on IDXX. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Finally, Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.